Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension

Pulmonary Hypertension Clinical Trial

— RHINO  

Official title:

Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02220634
• Other study ID #: HS-2820
• Status: Terminated
• Phase: N/A
• Start date: August 2014
• Est. completion date: May 25, 2017

Study information

• Verified date: January 2021
• Source: National Jewish Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to see if Regadenoson may offer improved ease of use, single dose administration, and better tolerance for testing for pulmonary hypertension than iNO. You will be screened to make sure Regadenoson is safe for you with a clinical evaluation, blood tests, and an ECG.

Description:

Pulmonary hypertension (PH) is an increase of blood pressure in the pulmonary vascular system that could cause shortness of breath, dizziness, leg swelling and heart failure. .

The diagnosis of PH requires confirmation of elevated pulmonary pressures.. Right heart catheterization (RHC) is a procedure to determine the diagnosis of PH. .

This research study is looking at the effect of intravenous infusion of the medication Regadenoson on pulmonary vasodilator response compared to the inhaled nitric oxide (iNO) response. iNO is the current standard of care practice.

The purpose of this study is to see if Regadenoson may offer improved ease of use, single dose administration, and better tolerance for testing for pulmonary hypertension than iNO. You will be screened to make sure Regadenoson is safe for you with a clinical evaluation, blood tests, and an ECG.

You will be asked to sign this informed consent form. Then, you will undergo right heart catheterization as part of your clinical care. Those who are positive for pulmonary hypertension will then undergo Regadenoson infusion and a inhaled iNO. Prior to the infusion, subjects will be asked if they have had in the last 12 hours any caffeine-containing foods or beverages, caffeine-containing medications such as theophylline 12 hours prior. Vital sign measurements will be taken to measure your heart. For those subjects that have low heart volume they will be given 500 cc of normal saline in their IV. Vital sign measurements will be taken again to make sure your heart volume is in the normal range. The doctor will administer Regadenoson 0.4 mg intravenously and this will cause your heart rate to increase. The doctor will be taking heart measurements 90 seconds, 5 minutes, 10 minutes, and 20 minutes after administration. Approximately 30 minutes after the Regadenoson has been administered you will be given iNO by facemask for 5 minutes.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: May 25, 2017
• Est. primary completion date: May 25, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age 18-75 years old

2. Diagnosis of RHC-proven PH

• Mean pulmonary artery pressure (mPAP) > 25 mmHg

• Pulmonary vascular resistance (PVR) > 3 woods units

• Pulmonary capillary wedge pressure (PCWP) < 15 mmHg).

Exclusion Criteria:

1. Second- or third-degree AV block or sinus node dysfunction

2. Known hypersensitivity to adenosine or regadenoson

3. Systolic blood pressure < 90mm Hg

4. Active bronchospasm

5. Autonomic dysfunction as defined by prior diagnosis of:

• Postural Orthostatic Tachycardia Syndrome (POTS)

• Neurocardiogenic Syncope (NCS)

• Neurally Mediated Hypotension (NMH)

• Vasovagal Syncope

6. Hypovolemia

7. > 40% Left main coronary stenosis

8. Moderate or > valvular stenosis

9. Pericarditis/pericardial effusions

10. > 70% carotid artery stenosis

11. Positive urine pregnancy test

Related Conditions & MeSH terms

• Hypertension
• Hypertension, Pulmonary
• Pulmonary Hypertension

Intervention

Drug:
• Regadenoson
Injection for intravenous administration

Locations

Country	Name	City	State
United States	National Jewish Health	Denver	Colorado

Sponsors (2)

Lead Sponsor	Collaborator
National Jewish Health	Astellas Pharma Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of people		5 years